Inhibitory effects and actions of pentacyclic triterpenes upon glycation

BioMedicine (Taiwan)

Volumn 5, Issue 3, 2015, Pages 1-8

  Yin, Mei Chin ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Advanced glycation end products; Glyoxalase; Pentacyclic triterpenes; Polyol pathway

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; NATURAL PRODUCT; PENTACYCLIC TRITERPENE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; CHRONIC DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; GLYCATION; HUMAN; MEDICAL INFORMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84939502808     PISSN: 22118020     EISSN: 22118039     Source Type: Journal    
DOI: 10.7603/s40681-015-0013-x     Document Type: Review

References (105)

1. McGarvey DJ, Croteau R. Terpenoid metabolism. Plant Cell 1997; 7: 1015-26.
2. Xu R, Fazio GC, Matsuda SPT. On the origins of triterpenoid skeletal diversity. Phytochemistry 2004; 65: 261-91.
3. Yin MC, Chan KC. Non-enzymatic antioxidative and antiglycative effects of oleanolic acid and ursolic acid. J Agric Food Chem 2007; 55: 7177-81.
4. Dennehy C. Botanicals in cardiovascular health. Clin Obstet Gynecol 2001; 44: 814-23.
5. Tolstikova TG, Khvostov MV, Bryzgalov AO. The complexes of drugs with carbohydrate-containing plant metabolites as pharmacologically promising agents. Mini Rev Med Chem 2009; 9: 1317-28.
6. Rodríguez-Rodríguez R, Herrera MD, Perona JS, Ruiz-Gutiérrez V. Potential vaso-relaxant effects of oleanolic acid and erythrodiol, two triterpenoids contained in 'orujo' olive oil, on rat aorta. Br J Nutr 2004; 92: 635-42.
7. Channa S, Dar A, Yaqoob M, Anjum S, Sultani Z. Bronchovasodilatory activity of fractions and pure constituents isolated from Bacopa monniera. J Ethnopharmacol 2003; 86: 27-35.
8. Eleuteri E, Magno F, Gnemmi I, Carbone M, Colombo M, La Rocca G, et al. Role of oxidative and nitrosative stress biomarkers in chronic heart failure. Front Biosci 2009; 14: 2230-7.
9. Calabrese V, Guagliano E, Sapienza M, Mancuso C, Butterfield DA, Stella AM. Redox regulation of cellular stress response in neurodegenerative disorders. Ital J Biochem 2006; 55: 263-82.
10. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol 2004; 24: 354-65.
11. Victor VM, Apostolova N, Herance R, Hernandez-Mijares A, Rocha M. Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy. Curr Med Chem 2009; 16: 4654-67.
12. Lau AT, Wang Y, Chiu JF. Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J Cell Biochem 2008; 104: 657-67.
13. Yao H, Yang SR, Kode A, Rajendrasozhan S, Caito S, Adenuga D, et al. Redox regulation of lung inflammation: role of NADPH oxidase and NF-kappaB signalling. Biochem Soc Trans 2007; 35: 1151-5.
14. Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int 2005; 9: 37-46.
15. Sudhahar V, Kumar SA, Varalakshmi P. Role of lupeol and lupeol linoleate on lipemic-oxidative stress in experimental hypercholesterolemia. Life Sci 2006; 78: 1329-35.
16. Laszczyk MN. Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med 2009; 75: 1549-60.
17. Bayón Y, Alonso A, Herna?ndez M, Nieto ML, Sánchez Crespo M. Mechanisms of cell signaling in immune mediated inflammation. Cytokines Cell Mol Ther 1998; 4: 275-86.
18. Conti P, DiGioacchino M. MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc 2001; 22: 133-7.
19. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-41.
20. Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007; 87: 1077-91.
21. Safayhi H, Sailer ER. Anti-inflammatory actions of pentacyclic triterpenes. Planta Med 1997; 63: 487-93.
22. Jung HW, Chung YS, Kim YS, Park YK. Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells. Exp Mol Med 2007; 39: 715-21.
23. ]. Banno N, Akihisa T, Tokuda H, Yasukawa K, Taguchi Y, Akazawa H, et al. Anti-inflammatory and antitumor promoting effects of the triterpene acids from the leaves of Eriobotrya japonica. Biol Pharm Bull 2005; 28: 1995-9.
24. Szuster-Ciesielska A, Plewka K, Daniluk J, Kandefer-Szerszen M. Betulin and betulinic acid attenuate ethanol-induced liver stellate cell activation by inhibiting reactive oxygen species (ROS), cytokine (TNF-α, TGF-β) production and by influencing intracellular signaling. Toxicology 2011; 280: 152-63.
25. Yan SL, Yang HT, Lee YJ, Lin CC, Chang MH, Yin MC. Asiatic acid ameliorates hepatic lipid accumulation and insulin resistance in mice consuming a high-fat diet. J Agric Food Chem 2014; 62: 4625-31.
26. Zhang X, Xiong H, Li H, Cheng Y. Protective effect of taraxasterol against LPS-induced endotoxic shock by modulating inflammatory responses in mice. Immunopharmacol Immunotoxicol 2014; 36: 11-6.
27. Ganguly A, Das B, Roy A, Sen N, Dasgupta SB, Mukhopadhayay S, et al. Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death. Cancer Res 2007; 67: 11848-58.
28. Hsia TC, Liu WH, Qiu WW, Luo J, Yin MC. Maslinic acid induces mitochondrial apoptosis and suppresses HIF-1α expression in A549 lung cancer cells under normoxic and hypoxic conditions. Molecules 2014; 19: 19892-906.
29. Yan SL, Huang CY, Wu ST, Yin MC. Oleanolic acid and ursolic acid induce apoptosis in four human liver cancer cell lines. Toxicol Vitro 2010; 24: 842-8.
30. Garo E, Eldridge GR, Goering MG, DeLancey Pulcini E. Hamilton MA, Costerton JW, et al. Asiatic acid and corosolic acid enhance the susceptibility of Pseudomonas aeruginosa biofilms to tobramycin. Antimicrob Agents Chemother 2007; 51: 1813-7
31. Wu HY, Chang CI, Lin BW, Yu FL, Lin PY, Hsu JL, et al. Suppression of hepatitis B virus x protein-mediated tumorigenic effects by ursolic acid. J Agric Food Chem 2011; 59: 1713-22.
32. Harada S. The broad anti-viral agent glycyrrhizin directly modulates ursolic acid. J Agric Food Chem 2011; 59: 1713-22. the fluidity of plasma membrane and HIV-1 envelope. Biochem J 2005; 392: 191-9.
33. do Nascimento PG, Lemos TL, Bizerra AM, Arriaga éM, Ferreira DA, Santiago GM, et al. Antibacterial and antioxidant activities of ursolic acid and derivatives. Molecules 2014; 19: 1317-27.
34. Kim J, Jang DS, Kim H, Kim JS. Anti-lipase and lipolytic activities of ursolic acid isolated from the roots of Actinidia arguta. Arch Pharm Res 2009; 32: 983-7.
35. Moon MH, Jeong JK, Lee YJ, Seol JW, Ahn DC, Kim IS, et al. 18β-Glycyrrhetinic acid inhibits adipogenic differentiation and stimulates lipolysis. Biochem Biophys Res Commun 2012; 420: 805-10.
36. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol a Biol Sci Med Sci 2007; 62: 427-33.
37. Kalousová M, Zima T, Tesar V, Dusilová-Sulková S, Skrha J. Advanced glycoxidation end products in chronic diseasesclinical chemistry and genetic background. Mutat Res 2005; 579: 37-46
38. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of man tissues in diabetes and aging. J Clin Invest 1997; 99: 457-68.
39. Toth E, Racz A, Toth J, Kaminski PM, Wolin MS, Bagi Z, et al. Contribution of polyol pathway to arteriolar dysfunction in hyperglycemia. Role of oxidative stress, reduced NO, and enhanced PGH(2)/ TXA(2) mediation. Am J Physiol Heart Circ Physiol 2007; 293: 3096-104.
40. Madhu SV, Verma NP, Goel A, Kapoor VK. Polyol pathway in the pathogenesis of diabetic complications and aldose reductase inhibitors. J Assoc Physicians India 1992; 40: 679-81
41. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int 2000; 58: 3-12.
42. Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M. TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med 2006; 6: 351-8.
43. Takeuchi M, Yamagishi S. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo. Med Hypotheses 2004; 63: 453-5.
44. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 1998; 101: 1142-7
45. Degenhardt TP, Thorpe SR, Baynes JW. Chemical modification of proteins by methylglyoxal. Cell Mol Biol (Noisy-le-grand) 1998; 44: 1139-45.
46. Nemet I, Varga-Defterdarovi-c L, Turk Z. Methylglyoxal in food and living organisms. Mol Nutr Food Res 2006; 50: 1105-17.
47. Mostafa AA, Randell EW, Vasdev SC, Gill VD, Han Y, Gadag V, et al. Plasma protein advanced glycation end products, carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with diabetes. Mol Cell Biochem 2007; 302: 35-42.
48. Takeuchi M, Sato T, Takino J, Kobayashi Y, Furuno S, Kikuchi S, et al. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease. Med Hypotheses 2007; 69: 1358-66.
49. Semba RD, Nicklett EJ, Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A Biol Sci Med Sci 2010; 65: 963-75.
50. Peppa M, Uribarri J, Vlassara H. Aging and glycoxidant stress. Hormones (Athens) 2008; 7: 123-32.
51. Negre-Salvayre A, Salvayre R, Augé N, Pamplona R, Portero-Otín M. Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal 2009; 11: 3071-109.
52. Tuttle KR, Anderberg RJ, Cooney SK, Meek RL. Oxidative stress mediates protein kinase C activation and advanced glycation end product formation in a mesangial cell model of diabetes and high protein diet. Am J Nephrol 2009; 29: 171-80.
53. Chandra KP, Shiwalkar A, Kotecha J, Thakkar P, Srivastava A, Chauthaiwale V, et al. Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects. Clin Drug Invest 2009; 29: 559-75.
54. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-42.
55. Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands JL, Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 2008; 7: 29.
56. Morcos M, Sayed AA, Bierhaus A, Yard B, Waldherr R, Merz W, et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002; 51: 3532-44.
57. Khan ZA, Chakrabarti S. Cellular signaling and potential new treatment targets in diabetic retinopathy. Exp Diabetes Res 2007; 2007: 31867.
58. Berrou J, Tostivint I, Verrecchia F, Berthier C, Boulanger E, Mauviel A, et al. Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells. Int J Mol Med 2009; 23: 513-20.
59. Ozdemir AM, Hopfer U, Rosca MV, Fan XJ, Monnier VM, Weiss MF. Effects of advanced glycation end product modification on proximal tubule epithelial cell processing of albumin. Am J Nephrol 2008; 28: 14-24.
60. Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des 2008; 14: 979e86.
61. Yamagishi S, Ueda S, Matsui T, Nakamura K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr Pharm Des 2008; 14: 962-8.
62. Armstrong RA. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease. Folia Neuropathol 2009;47: 289-99.
63. Reddy VP, Obrenovich ME, Atwood CS, Perry G, Smith MA. Involvement of Maillard reactions in Alzheimer disease. Neurotox Res 2002; 4: 191-209.
64. Takeda A, Wakai M, Niwa H, Dei R, Yamamoto M, Li M, et al. Neuronal and glial advanced glycation end product [Nepsilon-(carboxymethyl)lysine] in Alzheimer's disease brains. Acta Neuropathol 2001; 101: 27-35.
65. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 2001; 171: 29-45.
66. Di Loreto S, Caracciolo V, Colafarina S, Sebastiani P, Gasbarri A, Amicarelli F. Methylglyoxal induces oxidative stress-dependent cell injury and up-regulation of interleukin-1beta and nerve growth factor in cultured hippocampal neuronal cells. Brain Res 2004; 1006: 157-67.
67. Seidl R, Schuller E, Cairns N, Lubec G. Evidence against increased glycoxidation in patients with Alzheimer's disease. Neurosci Lett 1997; 232: 49-52.
68. Bär KJ, Franke S, Wenda B, Müller S, Kientsch-Engel R, Stein G, et al. Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Neurobiol Aging 2003; 24: 333-8.
69. Castellani RJ, Harris PL, Sayre LM, Fujii J, Taniguchi N, Vitek MP, et al. Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic Biol Med 2001; 31: 175-80.
70. Perez-Gracia E, Blanco R, Carmona M, Carro E, Ferrer I. Oxidative stress damage and oxidative stress responses in the choroid plexus in Alzheimer's disease. Acta Neuropathol 2009; 118: 497-504.
71. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997; 23: 134-47.
72. D'Agati V, Schmidt AM. RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol 2010; 6: 352-60.
73. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Dietderived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann NY Acad Sci 2005; 1043: 461-6.
74. Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer's disease: a progression factor for amyloid-beta induced cellular perturbation? J Alzheimers Dis 2009; 16: 833-43.
75. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498: 99-111.
76. Yan SF, Barile GR, D'Agati V, Du Yan S, Ramasamy R, Schmidt AM. The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications. Curr Diab Rep 2007; 7: 146-53.
77. Shanmugam N, Kim YS, Lanting L, Natarajan R. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J Biol Chem 2003; 278: 34834-44.
78. Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med 2007; 7: 711-24.
79. Yamagishi S. Advanced glycation end products and receptor-oxi-dative stress system in diabetic vascular complications. Ther Apher Dial 2009; 13: 534-9.
80. Lin L, Park S, Lakatta EG. RAGE signaling in inflammation and arterial aging. Front Biosci 2009; 14: 1403-13.
81. Gawlowski T, Stratmann B, Ruetter R, Buenting CE, Menart B, Weiss J, et al. Advanced glycation end products strongly activate platelets. Eur J Nutr 2009; 48: 475-81.
82. Nah SS, Choi IY, Yoo B, Kim YG, Moon HB, Lee CK. Advanced glycation end products increases matrix metalloproteinase-1, -3, and -13, and TNF-alpha in human osteoarthritic chondrocytes. FEBS Lett 2007; 581: 1928-32.
83. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 2010; 391: 1405-8.
84. Liu Y, Liang C, Liu X, Liao B, Pan X, Ren Y, et al. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-kappaB pathways. Atherosclerosis 2010; 208: 34-42.
85. Tan AL, Sourris KC, Harcourt BE, Thallas-Bonke V, Penfold S, Andrikopoulos S, et al. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2010; 298: 763-70.
86. Goldberg T, Cai W, Melpomeni P, Dardaine V, Baliga BS, Uribarri J, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Ass 2004; 104: 1287-91.
87. Chao PC, Hsu CC, Yin MC. Analysis of glycative products in sauces and sauce-treated foods. Food Chem 2009; 113: 262-6.
88. Erbersdobler HF, Somoza V. Forty years of furosine-forty years of using Maillard reaction products as indicators of the nutritional quality of foods. Mol Nutr Food Res 2007; 51: 423-30.
89. Motomura K, Fujiwara Y, Kiyota N, Tsurushima K, Takeya M, Nohara T, et al. Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced glycation end products. J Agric Food Chem 2009; 57: 7666-72.
90. Rao AR, Veeresham C, Asres K. In vitro and in vivo inhibitory activities of four Indian medicinal plant extracts and their major components on rat aldose reductase and generation of advanced glycation endproducts. Phytother Res 2013; 27: 753-60.
91. Maramaldi G, Togni S, Franceschi F, Lati E. Anti-inflammaging and antiglycation activity of a novel botanical ingredient from African biodiversity (Centevita™). Clin Cosmet Investig Dermatol 2013; 7: 1-9.
92. Kim JM, Jang DS, Lee YM, Yoo JL, Kim YS, Kim JH, et al. Aldosereductase-and protein-glycation-inhibitory principles from the whole plant of Duchesnea chrysantha. Chem Biodivers 2008; 5: 352-6.
93. Liu Y, Hartley DP, Liu J. Protection against carbon tetrachloride hepatotoxicity by oleanolic acid is not mediated through metallothionein. Toxicol Lett 1998; 95: 77-85.
94. Nguemfo EL, Dimo T, Dongmo AB, Azebaze AG, Alaoui K, Asongalem AE, et al. Anti-oxidative and anti-inflammatory activities of some isolated constituents from the stem bark of Allanblackia monticola Staner L.C (Guttiferae). Inflammopharmacology 2009; 17: 37-41.
95. Yamaguchi Y, Yamada K, Yoshikawa N, Nakamura K, Haginaka J, Kunitomo M. Corosolic acid prevents oxidative stress, inflammation and hypertension in SHR/NDmcr-cp rats, a model of metabolic syndrome. Life Sci 2006; 9: 2474-9.
96. Yan SL, Yang HT, Lee HL, Yin MC. Protective effects of maslinic acid against alcohol-induced acute liver injury in mice. Food Chem Toxicol 2014; 74: 149-55.
97. Wang ZH, Hsu CC, Huang CN, Yin MC. Anti-glycative effects of oleanolic acid and ursolic acid in kidney of diabetic mice. Eur J Pharmacol 2010; 628: 255-60.
98. Jang SM, Kim MJ, Choi MS, Kwon EY, Lee MK. Inhibitory effects of ursolic acid on hepatic polyol pathway and glucose production in streptozotocin-induced diabetic mice. Metabolism 2010; 59: 512-9.
99. Wang ZH, Hsieh CH, Liu WH, Yin MC. Glycyrrhizic acid attenuated glycative stress in kidney of diabetic mice through enhancing glyoxalase pathway. Mol Nutr Food Res 2014; 58: 1426-35.
100. Tsai SJ, Yin MC. Anti-glycative and anti-inflammatory effects of protocatechuic acid in brain of mice treated by D-galactose. Food Chem Toxicol 2012; 50: 3198-205.
101. Feng L, Zhu MM, Zhang MH, Wang RS, Tan XB, Song J, et al. Protection of glycyrrhizic acid against AGEs-induced endothelial dysfunction through inhibiting RAGE/NF-êB pathway activation in human umbilical vein endothelial cells. J Ethnopharmacol 2013; 148: 27-36.
102. Lu J, Wu DM, Zheng YL, Hu B, Zhang ZF, Ye Q, et al. Ursolic acid attenuates D-galactose-induced inflammatory response in mouse prefrontal cortex through inhibiting AGEs/RAGE/NF-êB pathway activation. Cereb Cortex 2010; 20: 2540-8.
103. Ueno M, Nakagawa T, Wu B, Onodera M, Huang CL, Kusaka T, et al. Transporters in the brain endothelial barrier. Curr Med Chem 2010; 17: 1125-38.
104. Pathan SA, Iqbal Z, Zaidi SM, Talegaonkar S, Vohra D, Jain GK, et al. CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul 2009; 3: 71-89.
105. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 2007; 7: 735-42.